Harvoni achieves 81-98% cure rates in hardest-to-treat patients
This article was originally published in Scrip
Executive Summary
Gilead has pulled more impressive data out of the bag for Sovaldi follow-on Harvoni (sofosbuvir and ledipasvir), this time showing that its hepatitis C virus (HCV) cure rates are still close to 100% even in the most difficult to treat patient groups, including those who have advanced liver disease and those who have failed on previous treatments.